- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07864415
High-Flow Tracheal Oxygen During Spontaneous Breathing Trial (HFTO-SBT)
Effect of High-flow Tracheal Oxygen on End-expiratory Lung Impedance and Work of Breathing in Intubated Patients During a Spontaneous Breathing Trial.
The purpose of this study is to find out whether high-flow tracheal oxygen (HFTO) delivered at flows greater than 60 L/min can increase end-expiratory lung volume (EELV) in intubated patients during a spontaneous breathing trial (SBT).
Weaning from mechanical ventilation can be difficult, especially in patients at higher risk of failure. During an SBT, losing positive end-expiratory pressure (PEEP) can cause the lungs to lose volume and make breathing harder by increasing the work of breathing (WOB). HFTO may help reduce the work of breathing, but previous studies using flows of 30-60 L/min did not consistently show an increase in EELV. Higher flows may create more airway pressure.
Therefore, the main question this study is trying to answer is: In intubated patients during an SBT, does HFTO at flows greater than 60 L/min increase EELV? The hypothesis is that HFTO at flows above 60 L/min will increase EELV during the SBT.
Przegląd badań
Status
Warunki
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Gustavo A Plotnikow, IP
- Numer telefonu: 5491164543771
- E-mail: gplotnikow@gmail.com
Lokalizacje studiów
-
-
-
Buenos Aires, Argentyna, 1280AEB
- Rekrutacyjny
- Hospital Británico de Buenos Aires
-
Kontakt:
- Gustavo Adrián Plotnikow, PhD, Head of Department
- Numer telefonu: +54 9 11 6454 3771
- E-mail: gplotnikow@gmail.com
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Age ≥ 18 years
- Invasive mechanical ventilation ≥ 24 hours
- Presence of esophageal balloon catheter
- Meets criteria to start an SBT
- Signed informed consent by patient or responsible family member
Exclusion Criteria:
- Neuromuscular or neurodegenerative disease
- contraindication to electrical impedance tomography (e.g., implantable defibrillator)
- Impossible to place EIT electrode belt (e.g., wound dressings or chest drains)
Elimination Criteria:
- Flow intolerance
- Behavioral/cognitive alterations that interrupt measurements in two consecutive attempts.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Zadanie krzyżowe
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Sequence A (HFTO 50 → HFTO 70)
|
Participants randomized to this Sequence receive the following conditions during a spontaneous breathing trial (SBT): T-piece (baseline) - 15 minutes High-flow tracheal oxygen (HFTO) at 50 L/min - 15 minutes Washout on T-piece - 15 minutes HFTO at 70 L/min - 15 minutes Washout on T-piece - 15 minutes Pressure support ventilation (PSV) 7 cmH₂O / PEEP 0 cmH₂O - 15 minutes Throughout the sequence, end-expiratory lung impedance (EELI), work of breathing (esophageal pressure-derived parameters), respiratory rate, SpO₂, hemodynamic variables, dyspnea, and diaphragmatic thickening fraction (DTF) are measured. This is one of two randomized crossover sequences; all participants receive all conditions in the order assigned by randomization. |
|
Eksperymentalny: Sequence B (HFTO 70 → HFTO 50)
|
Participants randomized to this Sequence receive the following conditions during a spontaneous breathing trial (SBT): T-piece (baseline) - 15 minutes High-flow tracheal oxygen (HFTO) at 70 L/min - 15 minutes Washout on T-piece - 15 minutes HFTO at 50 L/min - 15 minutes Washout on T-piece - 15 minutes Pressure support ventilation (PSV) 7 cmH₂O / PEEP 0 cmH₂O - 15 minutes Throughout the sequence, end-expiratory lung impedance (EELI), work of breathing (esophageal pressure-derived parameters: ΔPes, PTPes, PTPes-min), respiratory rate, SpO₂, hemodynamic variables, dyspnea, and diaphragmatic thickening fraction (DTF) are measured. This is one of two randomized crossover sequences; all participants receive all conditions in the order assigned by randomization. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in end-expiratory lung impedance (EELI) during spontaneous breathing trial
Ramy czasowe: Baseline (t0, T-piece); after 15 minutes of HFTO 50 L/min; after 15 minutes of HFTO 70 L/min; after 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with 15 minutes T-piece washout periods between conditions.
|
Change in global end-expiratory lung impedance (ΔEELI; arbitrary units), measured by electrical impedance tomography (EIT), expressed as tidal variation of the first stable respiratory cycle, among four conditions in intubated adult patients during a spontaneous breathing trial: T-piece, high-flow tracheal oxygen (HFTO) at 50 L/min, HFTO at 70 L/min, and pressure support ventilation (PSV) 7 cmH₂O / PEEP 0 cmH₂O. Because this is a randomized crossover study, the primary comparison is within-subject across conditions. |
Baseline (t0, T-piece); after 15 minutes of HFTO 50 L/min; after 15 minutes of HFTO 70 L/min; after 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with 15 minutes T-piece washout periods between conditions.
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in esophageal pressure swing
Ramy czasowe: Baseline (t0, T-piece); after 15 minutes of HFTO 50 L/min; after 15 minutes of HFTO 70 L/min; after 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with 15 minutes T-piece washout periods between conditions.
|
Change in esophageal pressure swing (ΔPes; units cmH2O) across conditions (T-piece, HFTO 50 L/min, HFTO 70 L/min, PSV 7 cmH₂O / PEEP 0 cmH₂O). |
Baseline (t0, T-piece); after 15 minutes of HFTO 50 L/min; after 15 minutes of HFTO 70 L/min; after 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with 15 minutes T-piece washout periods between conditions.
|
|
Change in Diaphragmatic Thickening Fraction (DTF)
Ramy czasowe: Baseline (t0, T-piece); at the end of 15 minutes of HFTO 50 L/min; at the end of 15 minutes of HFTO 70 L/min; at the end of 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with 15 minutes T-piece washout periods between conditions.
|
Change in diaphragmatic thickening fraction (DTF; Units percentage) measured by ultrasonography, calculated as: DTF = [(thickness at end-inspiration - thickness at end-expiration) / thickness at end-expiration] × 100. |
Baseline (t0, T-piece); at the end of 15 minutes of HFTO 50 L/min; at the end of 15 minutes of HFTO 70 L/min; at the end of 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with 15 minutes T-piece washout periods between conditions.
|
|
Respiratory rate
Ramy czasowe: Baseline (t0, T-piece); after 15 minutes of HFTO 50 L/min; after 15 minutes of HFTO 70 L/min; after 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with T-piece washout periods between conditions.
|
Number of ventilatory cicles per minute |
Baseline (t0, T-piece); after 15 minutes of HFTO 50 L/min; after 15 minutes of HFTO 70 L/min; after 15 minutes of PSV 7 cmH₂O/PEEP 0 cmH₂O; with T-piece washout periods between conditions.
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Days of invasive mechanical ventilation to weaning
Ramy czasowe: Baseline
|
Days of invasive mechanical ventilation from the intubation to the first weaning attempt |
Baseline
|
|
ICU length of stay
Ramy czasowe: From ICU admission through ICU discharge or death, assessed up to [28 days] after enrollment/randomization.
|
Duration of stay in the intensive care unit (ICU) from ICU admission to ICU discharge or death, whichever occurs first (Units; days) |
From ICU admission through ICU discharge or death, assessed up to [28 days] after enrollment/randomization.
|
|
ICU mortality
Ramy czasowe: Through ICU discharge or up to [28 days] after enrollment/randomization.
|
Number of participants who died in the ICU. |
Through ICU discharge or up to [28 days] after enrollment/randomization.
|
Współpracownicy i badacze
Publikacje i pomocne linki
Publikacje ogólne
- Parke RL, Bloch A, McGuinness SP. Effect of Very-High-Flow Nasal Therapy on Airway Pressure and End-Expiratory Lung Impedance in Healthy Volunteers. Respir Care. 2015 Oct;60(10):1397-403. doi: 10.4187/respcare.04028. Epub 2015 Sep 1.
- Stripoli T, Spadaro S, Di Mussi R, Volta CA, Trerotoli P, De Carlo F, Iannuzziello R, Sechi F, Pierucci P, Staffieri F, Bruno F, Camporota L, Grasso S. High-flow oxygen therapy in tracheostomized patients at high risk of weaning failure. Ann Intensive Care. 2019 Jan 7;9(1):4. doi: 10.1186/s13613-019-0482-2.
- Natalini D, Grieco DL, Santantonio MT, Mincione L, Toni F, Anzellotti GM, Eleuteri D, Di Giannatale P, Antonelli M, Maggiore SM. Physiological effects of high-flow oxygen in tracheostomized patients. Ann Intensive Care. 2019 Oct 7;9(1):114. doi: 10.1186/s13613-019-0591-y.
- Baydur A, Behrakis PK, Zin WA, Jaeger M, Milic-Emili J. A simple method for assessing the validity of the esophageal balloon technique. Am Rev Respir Dis. 1982 Nov;126(5):788-91. doi: 10.1164/arrd.1982.126.5.788.
- Acute Respiratory Distress Syndrome Network; Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000 May 4;342(18):1301-8. doi: 10.1056/NEJM200005043421801.
- Fernandez MM, Gonzalez-Castro A, Magret M, Bouza MT, Ibanez M, Garcia C, Balerdi B, Mas A, Arauzo V, Anon JM, Ruiz F, Ferreres J, Tomas R, Alabert M, Tizon AI, Altaba S, Llamas N, Fernandez R. Reconnection to mechanical ventilation for 1 h after a successful spontaneous breathing trial reduces reintubation in critically ill patients: a multicenter randomized controlled trial. Intensive Care Med. 2017 Nov;43(11):1660-1667. doi: 10.1007/s00134-017-4911-0. Epub 2017 Sep 22.
- Plotnikow GA, Thille AW, Vasquez DN, Pratto RA, Quiroga CM, Andrich ME, Dorado JH, Gomez RS, D'Annunzio PA, Scapellato JL, Intile D. Effects of High-Flow Nasal Cannula on End-Expiratory Lung Impedance in Semi-Seated Healthy Subjects. Respir Care. 2018 Aug;63(8):1016-1023. doi: 10.4187/respcare.06031. Epub 2018 Jun 26.
- Corley A, Edwards M, Spooner AJ, Dunster KR, Anstey C, Fraser JF. High-flow oxygen via tracheostomy improves oxygenation in patients weaning from mechanical ventilation: a randomised crossover study. Intensive Care Med. 2017 Mar;43(3):465-467. doi: 10.1007/s00134-016-4634-7. Epub 2016 Nov 30. No abstract available.
- Pham T, Heunks L, Bellani G, Madotto F, Aragao I, Beduneau G, Goligher EC, Grasselli G, Laake JH, Mancebo J, Penuelas O, Piquilloud L, Pesenti A, Wunsch H, van Haren F, Brochard L, Laffey JG; WEAN SAFE Investigators. Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE): a multicentre, prospective, observational cohort study. Lancet Respir Med. 2023 May;11(5):465-476. doi: 10.1016/S2213-2600(22)00449-0. Epub 2023 Jan 21.
- Janssen ML, Weller D, Endeman H, Heunks LM, Wils EJ. Physiological Effects of High-Flow Tracheal Oxygen in Tracheostomized Patients Weaning From Mechanical Ventilation. Respir Care. 2024 Sep 26;69(10):1336-1344. doi: 10.4187/respcare.11755.
- Lopez-Rubio AG, Torres-Suarez Y, Ortiz-Moreno DC, Perez-Velazquez CA, Castillo-Morales LM, Mora-Salamanca AF, Alvarado-Sanchez JI. High-flow tracheal therapy vs. tracheostomy mask in weaning: insights from a propensity-matched cohort. BMC Pulm Med. 2025 Nov 21;26(1):9. doi: 10.1186/s12890-025-04037-6.
- Khazaei O, Laffey CM, Sheerin R, McNicholas BA, Pham T, Heunks L, Bellani G, Brochard L, Simpkin AJ, Laffey JG; WEAN SAFE Investigators. Impact of comorbidities on management and outcomes of patients weaning from invasive mechanical ventilation: insights from the WEAN SAFE study. Crit Care. 2025 Mar 13;29(1):114. doi: 10.1186/s13054-025-05341-7.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Inne numery identyfikacyjne badania
- PRIISA 20291
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- ICF
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .